Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jayant S Sanghvi
Sun Pharma drops the ball again at Halol plant
Sun Pharma, for its Halol plant, got another form 483, which is issued when USFDA finds lapses in compliance, with three observations
US FDA flags issues at Sun Pharma's Halol plant
US FDA has issued a Form 483 with three observations after inspecting the Halol plant in Gujarat, for failing to meet good manufacturing practice standards, says Sun Pharma Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has now received the revised disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jayant S Sanghvi Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jayant S Sanghvi Sun Pharma recalls over 17,500 bottles of nasal spray solution from US
The bottles are being recalled following a failure to meet the % RSD requirement in the test for Droplet Size during the 6 month long term stability test station Announcement under Regulation 30 (LODR)-Updates on Acquisition
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raksha Sudhir Valia Sun Pharma eclipsed by 75% fall in Q3 net profit on weak US business
The results were below Bloomberg's revenue and profit estimate by over 5 per cent and 61 per cent, respectively